- Joined
- 3 May 2019
- Posts
- 6,321
- Reactions
- 9,981
At the current SP of $1.63, i would expect a bit of a flurry on the SPP at $1.45 for around $5 mil.
Will be interesting to see if it closes early.
Chart looking interesting also, almost like it wants to break out?, however, I would expect some tethering to the SPP price to keep a lid on things for a while...however US chipmakers up nicely overnight, so who knows?
Yep, a little tethered to that $1.45 price untill SPP closed.It's right on significant resistance at 1.63 and about to hit 20d sma. Would be a feat to get straight through.
Closing early, doubled toAt the current SP of $1.63, i would expect a bit of a flurry on the SPP at $1.45 for around $5 mil.
Will be interesting to see if it closes early.
Looks like the uptrend has resumed, at least on this shorter-term time scale.A quick squiz at the chart and the accumulation/ distribution indicator.
A 3 month daily chart shows an upturn in accumulation.
More pronounced on a 1 month chart, see below.
To me, this confirms my bias of "untethering" from recent CR/SPP price of $1.45
I suspect most profit takers have been shaken out by now...?
View attachment 132403
Looking at a 3 month or 6 month chart, I'm seeing a rounded double bottom.Interesting, I wasn't aware of Archers other deep tech research in medical diagnostics "Lab in a chip".
Today's price BO of the ledge looks promising.
I think they both have some merit.What I'm really wondering is;
if double bottoms are seen as bullish, is a sharp w pattern more attractive as a signal, or a smooth rounded one?
Where’s the rocket?Hot off the press.
ASX Announcement (ASX: AXE)
1 December 2021
Archer develops sensing pathways to detect genetic
information
Highlights
• Archer has developed its first biochemical reactions for application in its
biochip technology.
• The reactions have the potential for on-chip detection and quantification of specific DNA or RNA fragments relevant to viruses and bacteria.
• The work is a significant step in the Company’s development of its biochip†, providing potential reaction mechanisms for the technology’s future operation and applications in disease detection.
• The biochip has been developed in-house by Archer staff and Archer owns 100% of the biochip technology intellectual property.
Might put a rocket onto it in the current Omicron market sentiment?
Discarded, out of rocket fuel on the back nine, after hitting a high of $3.08 earlier in the year...Where’s the rocket?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?